M&A / Deals Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout BioPharma DiveThe deal secures two sleep disorder drugs that would fill a hole in the company s portfolio and intensify a competition with Takeda and Eisai.M&A / DealsNeuroscienceRead full story pharminent March 31, 2026 (Last updated: April 1, 2026) BioPharma Dive The deal secures two sleep disorder drugs that would fill a hole in the company s portfolio and intensify a competition with Takeda and Eisai. M&A / DealsNeuroscienceRead full story Post navigation Previous: Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis BuyNext: Novo hits back at rivals with cut-price Wegovy subscriptions Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026